Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
🇫🇷 FR Market
Global
United States
Australia
United Kingdom
Canada
India
China
Argentina
Austria
Bahrain
Bangladesh
Belgium
Bermuda
Botswana
Brazil
Bulgaria
Chile
Colombia
Croatia
Cyprus
Czech Republic
Denmark
Egypt
Estonia
Finland
France
Germany
Ghana
Greece
Hong Kong
Hungary
Iceland
Indonesia
Ireland
Israel
Italy
Ivory Coast
Jamaica
Japan
Jordan
Kenya
Kuwait
Latvia
Lithuania
Luxembourg
Malawi
Malaysia
Malta
Mauritius
Mexico
Morocco
Namibia
Netherlands
New Zealand
Nigeria
Norway
Oman
Pakistan
Palestinian Authority
Peru
Philippines
Poland
Portugal
Qatar
Romania
Russia
Saudi Arabia
Serbia
Singapore
Slovakia
Slovenia
South Africa
South Korea
Spain
Sri Lanka
Sweden
Switzerland
Taiwan
Tanzania
Thailand
Trinidad & Tobago
Tunisia
Turkey
Uganda
Ukraine
United Arab Emirates
Venezuela
Vietnam
Zambia
Zimbabwe
Healthcare
Any
Automobiles
Banks
Capital Goods
Commercial Services
Consumer Durables
Consumer Services
Diversified Financials
Energy
Consumer Retailing
Food, Beverage & Tobacco
Healthcare
Household
Insurance
Materials
Media
Pharmaceuticals & Biotech
Real Estate
Retail
Semiconductors
Software
Tech
Telecom
Transportation
Utilities
Create a narrative
Community
/
France
/
Healthcare
Healthcare French Community
Our community narratives are driven by numbers and valuation.
Create a narrative
Healthcare French Investing Ideas
All companies
Popular
Undervalued
Overvalued
EssilorLuxottica Société anonyme
LO
London_Investment_Analysts
Community Contributor
EssilorLuxottica: Pioneering the Future of Eyewear through Innovation and Strategic Expansion
EssilorLuxottica, a global leader in the design, manufacture, and distribution of ophthalmic lenses, frames, and sunglasses, continues to redefine the eyewear industry through technological innovation and strategic acquisitions. With a diverse portfolio that includes iconic brands like Oakley and the recent addition of Supreme, the company is poised to enhance its market presence and consumer engagement.
View narrative
€400.08
FV
31.4% undervalued
intrinsic discount
13.65%
Revenue growth p.a.
Set Fair Value
1
users have liked this narrative
0
users have commented on this narrative
6
users have followed this narrative
7 months ago
author updated this narrative
CLAR
Clariane
AN
AnalystHighTarget
Consensus Narrative from 6 Analysts
Aging Demographics And Digital Tools Will Fuel Resilient Recovery
Key Takeaways Portfolio refocusing, operational efficiency gains, and advanced data analytics are set to boost margins, cash flow, and organic earnings growth over the long term. Demographic trends, regulatory advantages, and investment in non-acute care infrastructure position Clariane for sustained market share gains and resilient revenue expansion.
View narrative
€6.8
FV
38.0% undervalued
intrinsic discount
6.42%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
8 days ago
author updated this narrative
EssilorLuxottica Société anonyme
AN
AnalystLowTarget
Consensus Narrative from 18 Analysts
Digital Commerce And Regulatory Risks Will Undercut Smart Eyewear
Key Takeaways Growing digital competition and shifting consumer trends threaten traditional sales channels, premium market focus, and long-term pricing power. Expansion into MedTech and innovative eyewear increases operational complexity, regulatory exposure, and execution risk, pressuring profitability and margin sustainability.
View narrative
€207.72
FV
32.2% overvalued
intrinsic discount
5.37%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
4
users have followed this narrative
8 days ago
author updated this narrative
EssilorLuxottica Société anonyme
AN
AnalystHighTarget
Consensus Narrative from 18 Analysts
Rising Screen Time And Global Aging Will Spur Optical Demand
Key Takeaways Innovation in myopia management and smart eyewear, supported by vertical integration and AI capabilities, positions the company for market dominance and expanding recurring revenue streams. Rising demand from emerging markets, healthcare adoption, and demographic shifts could drive sustained revenue and earnings growth, outperforming industry peers in resilience and profitability.
View narrative
€305
FV
10.0% undervalued
intrinsic discount
7.21%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
2
users have followed this narrative
8 days ago
author updated this narrative
Cegedim
AN
AnalystConsensusTarget
Consensus Narrative from 3 Analysts
Visiodent Integration And Allianz Contract Will Improve Future Profitability In Healthcare Software
Key Takeaways Internalizing the workforce, especially for Allianz, could cut external costs and boost profitability. The simpler software launch may enhance market share and revenue within the French healthcare software market.
View narrative
€13.67
FV
26.8% undervalued
intrinsic discount
2.98%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
1
users have followed this narrative
15 days ago
author updated this narrative
EssilorLuxottica Société anonyme
AN
AnalystConsensusTarget
Consensus Narrative from 18 Analysts
Advancing Myopia Management Will Unlock Global MedTech Potential
Key Takeaways Ongoing innovation in vision solutions and smart eyewear, along with strategic acquisitions, enhances competitive advantage and supports future market share and profitability. Global expansion, supply chain diversification, and direct-to-consumer initiatives drive top-line growth, operational resilience, and recurring revenue opportunities.
View narrative
€265.94
FV
3.2% overvalued
intrinsic discount
6.13%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
27
users have followed this narrative
15 days ago
author updated this narrative
CLAR
Clariane
AN
AnalystConsensusTarget
Consensus Narrative from 6 Analysts
Refinancing And French Pricing Will Pressure Margins But Build Resilience
Key Takeaways Ongoing disposal plan and deleveraging efforts may limit opportunistic growth and reduce future revenue streams. Margin pressures and refinancing could impact profitability and financial flexibility, constraining revenue and earnings growth.
View narrative
€5.16
FV
18.2% undervalued
intrinsic discount
4.82%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
4
users have followed this narrative
15 days ago
author updated this narrative
bioMérieux
AN
AnalystConsensusTarget
Consensus Narrative from 14 Analysts
Continued Innovation And Market Leadership Will Ensure Future Success
Key Takeaways Strong cross-selling and innovation strategies are driving revenue growth and expanding market leadership in panel and instrument installations. Profitability improvements through automation and R&D investment are enhancing margins and supporting sustainable long-term growth.
View narrative
€123.46
FV
7.7% undervalued
intrinsic discount
7.10%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
3
users have followed this narrative
15 days ago
author updated this narrative
Cegedim
AN
AnalystLowTarget
Consensus Narrative from 3 Analysts
Legacy Challenges Will Test Healthcare Digitalization As Modest Opportunities Open
Key Takeaways Legacy IT reliance and underperformance in core divisions constrain growth, as newer digital competitors erode market share and hinder innovation. Limited international success and tightening regulatory demands restrict diversification, keeping growth dependent on mature home markets and pressuring profitability.
View narrative
€11
FV
9.1% undervalued
intrinsic discount
3.39%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
15 days ago
author updated this narrative